Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

T Hansen; R P Hemmingsen; A G Wang; L Olsen; S Timm; Karen Søeby; K D Jakobsen; M Fenger; J Parnas; H B Rasmussen; T Werge; Thomas Folkmann Hansen

doi:http://dx.doi.org/10.1038/sj.tpj.6500350

Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

T Hansen, R P Hemmingsen, A G Wang, L Olsen, S Timm, Karen Søeby, K D Jakobsen, M Fenger, J Parnas, H B Rasmussen, T Werge, Thomas Folkmann Hansen

15 Citations (Scopus)

Abstract

Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.

Original language	English
Journal	Pharmacogenomics Journal
Volume	6
Issue number	2
Pages (from-to)	120-5
Number of pages	6
ISSN	1470-269X
DOIs	https://doi.org/10.1038/sj.tpj.6500350
Publication status	Published - 2006

Access to Document

http://dx.doi.org/10.1038/sj.tpj.6500350

http://www.nature.com/tpj/journal/v6/n2/abs/6500350a.html;jsessionid=FE3629C7D0E24CEF259C19D31DB08987

Cite this

@article{e3600ae070eb11dcbee902004c4f4f50,

title = "Apolipoprotein D is associated with long-term outcome in patients with schizophrenia",

abstract = "Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.",

author = "T Hansen and Hemmingsen, {R P} and Wang, {A G} and L Olsen and S Timm and Karen S{\o}eby and Jakobsen, {K D} and M Fenger and J Parnas and Rasmussen, {H B} and T Werge and Hansen, {Thomas Folkmann}",

year = "2006",

doi = "http://dx.doi.org/10.1038/sj.tpj.6500350",

language = "English",

volume = "6",

pages = "120--5",

journal = "The Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "nature publishing group",

number = "2",

}

TY - JOUR

T1 - Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

AU - Hansen, T

AU - Hemmingsen, R P

AU - Wang, A G

AU - Olsen, L

AU - Timm, S

AU - Søeby, Karen

AU - Jakobsen, K D

AU - Fenger, M

AU - Parnas, J

AU - Rasmussen, H B

AU - Werge, T

AU - Hansen, Thomas Folkmann

PY - 2006

Y1 - 2006

N2 - Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.

AB - Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.

U2 - http://dx.doi.org/10.1038/sj.tpj.6500350

DO - http://dx.doi.org/10.1038/sj.tpj.6500350

M3 - Journal article

SN - 1470-269X

VL - 6

SP - 120

EP - 125

JO - The Pharmacogenomics Journal

JF - The Pharmacogenomics Journal

IS - 2

ER -

Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

Abstract

Access to Document

Fingerprint

Cite this